With the date for Brexit rapidly approaching, the realisation is hitting home with British Biotechs that business operations and practices that have been followed for years may not now be sustainable or profitable in the the uncertain times ahead.
Equally, uncertainty for some can mean opportunity for others, so how can companies and investors evaluate the market correctly in order to contine or even increase their ROI?
At the Phacilitate Leaders event in January, Phacilitate had the chance to talk to Matthew Durdy at Cell and Gene Therapy Catapult to find out just that. Matthew tells us what the UK biotech industry looks like post-brexit, the step-by-step process that should be followed in order to bring a novel therapeutic to trial, and the support that Cell and Gene Therapy Catapult can give to accelerate the development of an advanced therapy.
Want to gain more insights just like this?
Register for the Investment for Advanced Therapies Summit now to gain more insights just like this, from all of the major players in the space, including, biotechs, pharma and investors. And with investors already invited to attend the event for free, there really will be something for everyone at the event!
Add Your Response